Visudyne

Visudyne

verteporfin

Manufacturer:

Alcami Carolinas Corporation

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Verteporfin
Indications/Uses
Patients w/ subfoveal choroidal neovascularisation ie, predominantly classic or occult & due to age-related macular degeneration, or due to pathologic myopia.
Dosage/Direction for Use
Adult including elderly ≥65 yr 1st step: 6 mg/m2 infused IV over 10 min. 2nd step: Light activation at 15 min after the start of the infusion. Patient should be re-evaluated every 3 mth & retreated in the event of recurrent CNV leakage (therapy may be given up to 4 times/yr).
Contraindications
Hypersensitivity. Porphyria. Severe hepatic impairment.
Special Precautions
Avoid exposure of unprotected skin, eyes & other body organs to direct sunlight or bright indoor light for 48 hr after infusion; wear protective clothing & dark sunglasses. If emergency surgery is necessary w/in 48 hr after treatment, protect the internal tissue from intense light. Patients who experience severe vision deterioration (≥4 lines) w/in 1 wk after treatment should not be treated again. Avoid extravasation. Medical supervision of patients during infusion is advised. Anaesth patients. Treatment of 2nd eye; use of incompatible lasers. Unstable heart disease (class III or IV & uncontrolled arterial HTN). Transient visual disturbances may develop that may interfere w/ ability to drive or use machines. Moderate to severe hepatic impairment or biliary obstruction. Renal impairment. Pregnancy & lactation. Childn.
Adverse Reactions
Visual impairment, reduced visual acuity, visual field defect; chest pain, asthenia, inj site oedema, inflammation, extravasation & pain; hypersensitivity; back pain; syncope, headache, dizziness; dyspnea; photosensitivity reaction.
Drug Interactions
Increased potential for photosensitivity reactions w/ photosensitizing agents (eg, tetracyclines, sulphonamides, phenothiazines, sulfonylurea, hypoglycemic agents, thiazide diuretics & griseofulvin). Altered vascular endothelium which may result in enhanced tissue-uptake w/ Ca channel blockers, polymyxin B & radiation therapy. Decreased activity w/ antioxidants (eg, β-carotene) or drugs that scavenge free radicals (eg, dimethylsulfoxide, formate, mannitol, or alcohol). Possible antagonism of action by vasodilators & those which diminish clotting & platelet aggregation (eg, thromboxane A2 inhibitors).
MIMS Class
Other Eye Preparations
ATC Classification
S01LA01 - verteporfin ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Visudyne inj 15 mg
Packing/Price
(vial) 1's ($2,666.67/box)
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in